You are here

FDA Approves Narcan Nasal Spray for Opioid Overdose

Two-milligram formulation green-lighted for emergency use

The FDA has given the nod to Narcan nasal spray (naloxone, Adapt Pharmaceuticals) as a 2-mg formulation for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. The 2-mg dose is approved for use in opioid-dependent patients expected to be at risk for severe opioid withdrawal in situations where there is a low risk for accidental or intentional opioid exposure by household contacts.

This approval comes approximately one year after the FDA green-lighted the first ready-to-use, needle-free version of naloxone, Narcan nasal spray 4 mg, which has been commercially available since February 2016 after expedited FDA review and approval.

Narcan nasal spray 2 mg and 4 mg are concentrated naloxone nasal sprays providing ready-to-use emergency treatments for opioid overdose, including overdose related to prescription opioid painkillers, fentanyl, carfentanil, or heroin. The product is not a substitute for emergency medical care.

Source: PR Newswire; January 25, 2017.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs
Acasti reports disappointing results for a second Omega-3-based drug
Declining lung cancer mortality helped fuel the progress